Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis

Thrombosis Research

Volumn 87, Issue 5, 1997, Pages 419-429

  Minix, R ^a   Doctor, V M ^a  

^a PRAIRIE VIEW A AND M UNIVERSITY   (United States)

Author keywords

AT III; Fucoidan; PAI 1; T PA; Thrombin; Urokinase

Indexed keywords

AMINOCAPROIC ACID; FUCOIDIN; HEPARIN COFACTOR II; PROTEINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BLOOD CLOTTING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SPECIFICITY; FIBRINOLYSIS; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTITHROMBIN III; BLOOD COAGULATION; ENDOPEPTIDASES; ENZYME ACTIVATION; FIBRINOLYSIS; HEMOSTASIS; HUMANS; KINETICS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYSACCHARIDES; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030838796     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00158-8     Document Type: Article

References (28)

1. ROSENBERG, D., and DAMUS, P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem.248,6490-6505,1973.
2. OLSON, S.T. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. J. Biol. Chem.263,1689-1708,1988.
3. nd Ed: pp.849-869,1987.
4. ANDRADE-GORDON, P. and STRICKLAND, S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry.25,4033-4040, 1986.
5. PAGUES, E.P., STOHR, H.A. and HEIMBURGER, N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system. Relationship between plasminogen activators and heparin. Thrombosis Research 42. 797-807, 1986.
6. EDELBERG, J.M. and PIZZO, S.V. Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry. 29, 5906-5911, 1990.
7. EDELBERG, J.M., WEISSLER, M and PIZZO, S.V. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. Biochem. J. 276, 785-791, 1991.
8. TAKADA, Y, URANO, T and TAKADA, A. Effects of heparan sulfate analogue or other sulfated polysaccharides on the activation of plasminogen by t-PA or u-PA. Thrombosis Research. 73, 301-311, 1994.
9. SPRINGER, G.R. WURZEL, H.A., MCNEIL, G.M. Jr., ANSELL, N.J. and DOUGHTY, M.F. Isolation of anticoagulant fractions from crude fucoidan. Proc. Soc. Exp. Biol. Med. 94, 404-409, 1957.
10. CHURCH, F.C., MEADE, J.B., TREANOR, R.E. and WHINNA, H.C. Antithrombin activity of fucoidan. J. Biol. Chem. 264, 3618-3623, 1989.
11. SOEDA, S. SAKAGUCHI, S. SHIMEN, H. and NAGAMATSU, A. Fibrinolytic and anticoagulant activities of highly sulfated fucoidan. Biochem. Pharmacol. 43, 1853-1858, 1992.
12. DOCTOR, V.M., HILL, C., and JACKSON, G.J. Effect of fucoidan during activation of human plasminogen. Thrombosis Research. 79, 237-247, 1995.
13. KATO, I and ANFINSEN, C.B. Purification of synthetic ribonucleases s-peptide derivatives by specific complex formation on columns of ribonuclease S-protein bound to agarose. J. Biol. Chem. 244, 5849-5855, 1969.
14. IVERIUS, P.H. Coupling of glycosaminoglycans to agarose beads (sepharose 4B). Biochem. J. 124, 677-683, 1971.
15. DUBOIS, M, GILLES, K.A., HAMILTON, J.K., REBERS, P.A. and SMITH, F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28, 350-354, 1956.
16. ZAWILSKA, K., ELIKOWSKI, W, TUROWIECKA, Z, ZOZULINSKA, M., GRZYWACZ, A., PRZYBYL, L. and VINAZZER, H. On the action of a heparin-like glycosaminoglycan (Hemovasal) on the mechanism of hemostasis and fibrinolysis. Thrombosis Research. 78, 211-216, 1995.
17. JUHAN-VAGUE, I., VALADIER, J., ALESSI, M. C., AILLAUD, M. F., ANSALDI, J., PHILLIP-JOET, C., HOLVOET, P., SERRADIMIGNI, A. and COLLEN, D. Deficient t-PA release and elevated t-PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57, 57-76, 1987.
18. JUHAN-VAGUE, I., ALESSI, M.C., JOLY, P., THIRION, S., VAGUE, P., DECLERK, P. J., SERRADIMIGNI, A. and COLLEN, D. Plasminogen activator inhibitor-1 in angina pectoris. Arteriosclerosis 9, 362-367, 1989.
19. KRUITHOF, E., GUDINCHET, A. and BACHMANN, F. Plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 in various disease states. Thromb. Haemost 59, 7-12, 1988.
20. FOEKENS, J. A., SCHMITT, M., VAN PUTTEN, W. L. J., PETERS, H., BONTENBAL, M., JANICKE, F. and KLIJN, F. G. M. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncology 12, 1648-1658, 1994.
21. JANICKE, F., SCHMITT, M., PACHE, L., ULM, K., HARBECK, N., HOFLER, H. and GRAEFF, H. Urokinase (UPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Research and Treatment 24, 195-208, 1993.
22. NEKARDA, H., SCHMITT, M., ULM, K., WENNINGER, A., VOGELSANG, H., BECKER, K., RODER, J. D., FINK, U. and SIEWERT, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastic cancer. Cancer Res. 54, 2900-2907, 1994.
23. DOCTOR, V. M., MINIX, R. and MUNEER, E. Unpublished Observation. 1997.
24. WILLIAMS, D. O., BORER, J., BRAUNWALD, E., CHESEBRO, J. H., COHEN, L. S., DODGE, H. T., FRANCIS, C. K., KNATTERND, G., LUDBROOK, P., MARKIS, J. E., MUELLER, H. and COINVESTIGATORS Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBL thrombolysis in myocardial infarction trial. Circulation 73, 338-346, 1986.
25. GOLD, H. K., LEINBACK, R. C., GARABEDIAN, H. D., YASUDA, T., JOHNS, J. A., CROSSBARD, E. B., PALACIOS, I. and COLLEN, D. Acute coronary reocclusion after thrombolysis and recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion. Circulation 73, 347-352, 1986.
26. WEITZ, J. I., HUDOBA, M., MASSEL, D. MARAGANORE, J. and HIRSH, J. Clot-bound thrombin is protected form inhibiton by heparin-antithrombin III but its susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86, 385-391, 1990.
27. HOGG, P. J. and JACKSON, C. M. Heparin promotes binding of thrombin to fibrin polymer. J. Biol. Chem. 265, 241-247, 1990.
28. HOGG, P. J. and JACKSON, C. M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin-III: Implications for heparin efficacy. Proc. Natl. Acad. Sci., U.S.A. 86, 3619-3623, 1989.